Volume 17, Issue 2, Pages 224-233 (February 2016) Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial Mark Glover, MFOM, Gary R Smerdon, PhD, H Jervoise Andreyev, PhD, Barbara E Benton, BN, Pieter Bothma, MMed [Anaesthesiology], Oliver Firth, MRCGP, Lone Gothard, HND, John Harrison, FRCA, Mihaela Ignatescu, MD, Gerard Laden, BSc, Sue Martin, BSc, Lauren Maynard, MSc, Des McCann, MRCGP, Christine E L Penny, MRCGP, Spencer Phillips, MBA, Grace Sharp, BSc, Prof John Yarnold, FRCR The Lancet Oncology Volume 17, Issue 2, Pages 224-233 (February 2016) DOI: 10.1016/S1470-2045(15)00461-1 Copyright © 2016 Glover et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure Trial profile IBDQ=modified Inflammatory Bowel Disease Questionnaire. *Includes one patient in the control group and two patients in the hyperbaric oxygen therapy group who received no treatment. The Lancet Oncology 2016 17, 224-233DOI: (10.1016/S1470-2045(15)00461-1) Copyright © 2016 Glover et al. Open Access article distributed under the terms of CC BY Terms and Conditions